CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.2.2.1. Competitive intelligence of companies and their strategies

3.3. MARKET SHARE ANALYSIS, 2015
3.4. MARKET DYNAMICS

3.4.1. Drivers

3.4.1.1. Growing prevalence of diabetes
3.4.1.2. Increasing incidence of blindness due to diabetes
3.4.1.3. Growing geriatric population
3.4.1.4. Increasing awareness for treatment of diabetic retinopathy

3.4.2. Restraints

3.4.2.1. Extended approval time for drugs
3.4.2.2. Dearth of skilled ophthalmologists

3.4.3. Opportunities

3.4.3.1. Lucrative opportunities in the emerging economies
3.4.3.2. Emergence of combined therapies

3.4.4. Impact analysis

3.5. CLINICAL TRIALS

CHAPTER 4 DIABETIC RETINOPATHY MARKET, BY TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. PROLIFERATIVE DIABETIC RETINOPATHY

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. DIABETIC MACULAR EDEMA

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

CHAPTER 5 DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ANTI-VEGF DRUG

5.2.1. Market size and forecast

5.3. STEROID IMPLANTS

5.3.1. Market size and forecast

5.4. LASER SURGERIES

5.4.1. Market size and forecast

5.5. VITRECTOMY

5.5.1. Market size and forecast

CHAPTER 6 DIABETIC RETINOPATHY MARKET, BY REGION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.4. U.S.
6.2.5. Canada
6.2.6. Mexico

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.4. Germany
6.3.5. France
6.3.6. UK
6.3.7. Italy
6.3.8. Spain
6.3.9. Rest of Europe

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.4. Japan
6.4.5. China
6.4.6. India
6.4.7. South Korea
6.4.8. Australia
6.4.9. Rest of Asia-Pacific

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.4. Brazil
6.5.5. South Africa
6.5.6. Saudi Arabia
6.5.7. Rest of LAMEA

CHAPTER 7 COMPANY PROFILES

7.1. ABBOTT LABORATORIES

7.1.1. Overview
7.1.2. Operating business segments
7.1.3. Business performance
7.1.4. Key strategic moves and developments

7.2. ALIMERA SCIENCE

7.2.1. Overview
7.2.2. Operating business segments
7.2.3. Business performance
7.2.4. Key strategic moves and developments

7.3. ALLERGAN PLC

7.3.1. Overview
7.3.2. Operating business segments
7.3.3. Business performance
7.3.4. Key strategic moves and developments

7.4. AMPIO PHARMACEUTICALS.

7.4.1. Company overview
7.4.2. Operating business segments
7.4.3. Business performance
7.4.4. Key strategic moves and developments

7.5. BAYER AG

7.5.1. Overview
7.5.2. Operating business segments
7.5.3. Business performance
7.5.4. Key strategic moves and developments

7.6. F. HOFFMANN-LA ROCHE

7.6.1. Company overview
7.6.2. Operating business segments
7.6.3. Business performance
7.6.4. Key strategic moves and developments

7.7. NOVARTIS INTERNATIONAL AG

7.7.1. Overview
7.7.2. Operating business segments
7.7.3. Business performance
7.7.4. Key strategic moves and developments

7.8. PFIZER

7.8.1. Overview
7.8.2. Operating business segments
7.8.3. Business performance
7.8.4. Key strategic moves and developments

7.9. REGENERON PHARMACEUTICALS INC.

7.9.1. Company overview
7.9.2. Operating business segments
7.9.3. Business performance
7.9.4. Key strategic moves and developments

7.10. VALEANT PHARMACEUTICAL

7.10.1. Overview
7.10.2. Operating business segments
7.10.3. Business performance
7.10.4. Key strategic moves and developments